Skip to main content
Top
Published in: Acta Neurologica Belgica 2/2019

01-06-2019 | Original Article

Interleukin-18 promoter polymorphisms and idiopathic Parkinson disease: an Egyptian study

Authors: Ebtesam Fahmy, Amany Rabah, Sahar Sharaf, Hanan Helmy, Ahmed Kamal

Published in: Acta Neurologica Belgica | Issue 2/2019

Login to get access

Abstract

Etiology of sporadic Parkinson’s disease (PD) is largely unknown. The contribution of genetic factors to the pathogenesis of PD is supported by the demonstration of high concordance in twins, increased risk among relatives of PD patients and existence of familial cases. This study aimed to examine the relation between interleukin 18 (IL-18) gene promoter polymorphisms and idiopathic PD, and its impact on clinical presentation and disease severity. 30 idiopathic PD patients and 15 age- and sex-matched healthy subjects were included. Disease severity was assessed using Unified Parkinson’s Disease Rating Scale (UPDRS). Genetic testing for IL-18 gene promoter −607C/A single nucleotide polymorphisms (SNP) was done using real-time polymerase chain reaction (PCR) technique. A raised risk of PD development was found in patients with A/C and C/C genotypes of the site −607C/A (odds ratios = 1.83 and 1.98, respectively). The distribution of the genotypes showed no significant relation to gender or predominant clinical presentation. The age at onset of disease was significantly lower in C/C and A/A genotypes compared to A/C genotype (p = 0.001 and 0.04, respectively). Patients with A/A genotype showed significantly higher mentation score of UPDRS compared to patients with A/C and C/C genotypes (p = 0.003 and p = 0.002, respectively). Polymorphisms of IL-18 gene promoter increase the risk of developing idiopathic PD. The polymorphisms may affect phenotypic expression rather than being a direct cause of idiopathic PD.
Literature
1.
go back to reference Fahn S, Przedborski S (2005) Parkinsonism. In: Rowland (ed) Merritt’s neurology. Lippincott Williams & Wilkins, Philadelphia, pp 828–846 Fahn S, Przedborski S (2005) Parkinsonism. In: Rowland (ed) Merritt’s neurology. Lippincott Williams & Wilkins, Philadelphia, pp 828–846
2.
go back to reference Sugama S, Wirz SA, Barr AM, Conti B, Bartfai T, Shibasaki T (2004) Interleukin-18 null mice show diminished microglial activation and reduced dopaminergic neuron loss following acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment. Neuroscience 128:451–458CrossRefPubMed Sugama S, Wirz SA, Barr AM, Conti B, Bartfai T, Shibasaki T (2004) Interleukin-18 null mice show diminished microglial activation and reduced dopaminergic neuron loss following acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment. Neuroscience 128:451–458CrossRefPubMed
3.
go back to reference Hunot S, Hirsch EC (2003) Neuroinflammatory processes in Parkinson’s disease. Ann Neurol 53(3):49–60CrossRef Hunot S, Hirsch EC (2003) Neuroinflammatory processes in Parkinson’s disease. Ann Neurol 53(3):49–60CrossRef
4.
go back to reference Pawlik A, Kurzawski M, Czerny B, Gawronska-Szklarz B, Drozdzik M, Herczynska M (2006) Interleukin-18 promoter polymorphism in patients with rheumatoid arthritis. Tissue Antigens 67:415–418CrossRefPubMed Pawlik A, Kurzawski M, Czerny B, Gawronska-Szklarz B, Drozdzik M, Herczynska M (2006) Interleukin-18 promoter polymorphism in patients with rheumatoid arthritis. Tissue Antigens 67:415–418CrossRefPubMed
5.
go back to reference Yu JT, Tan L, Song JH, Sun YP, Chen W, Miao D, Tian Y (2009) Interleukin-18 promoter polymorphisms and risk of late onset Alzheimer’s disease. Brain Res 1253:169–175CrossRefPubMed Yu JT, Tan L, Song JH, Sun YP, Chen W, Miao D, Tian Y (2009) Interleukin-18 promoter polymorphisms and risk of late onset Alzheimer’s disease. Brain Res 1253:169–175CrossRefPubMed
6.
go back to reference Xu X, Li D, He Q, Gao J, Chen B, Xie A (2011) Interleukin-18 promoter polymorphisms and risk of Parkinson’s disease in a Han Chinese population. Brain Res 1381:90–94CrossRefPubMed Xu X, Li D, He Q, Gao J, Chen B, Xie A (2011) Interleukin-18 promoter polymorphisms and risk of Parkinson’s disease in a Han Chinese population. Brain Res 1381:90–94CrossRefPubMed
8.
go back to reference Jankovic J, Shannon MK (2008) Movement disorders. In: Bradley W, Daroff R, Fenichel G, Jankovic J (eds) Neurology in clinical practice. Butterworth Heinmann, Elsevier, Amsterdam, pp 2081–2122CrossRef Jankovic J, Shannon MK (2008) Movement disorders. In: Bradley W, Daroff R, Fenichel G, Jankovic J (eds) Neurology in clinical practice. Butterworth Heinmann, Elsevier, Amsterdam, pp 2081–2122CrossRef
9.
go back to reference Brusse KJ, Zimdars S, Zalewski KR, Steffen TM (2005) Testing functional performance in people with Parkinson’s disease. Phys Ther 85:134–141PubMed Brusse KJ, Zimdars S, Zalewski KR, Steffen TM (2005) Testing functional performance in people with Parkinson’s disease. Phys Ther 85:134–141PubMed
11.
go back to reference Hakansson A, Westberg L, Nilsson S, Buervenich S, Carmine A, Holmberg B, Sydow O, Olson L, Johnels B, Eriksson E, Nissbrandt H (2005) Interaction of polymorphisms in the genes encoding interleukin-6 and estrogen receptor Beta on the susceptibility to Parkinson’s disease. Am J Med Genet 133(B):88–92CrossRef Hakansson A, Westberg L, Nilsson S, Buervenich S, Carmine A, Holmberg B, Sydow O, Olson L, Johnels B, Eriksson E, Nissbrandt H (2005) Interaction of polymorphisms in the genes encoding interleukin-6 and estrogen receptor Beta on the susceptibility to Parkinson’s disease. Am J Med Genet 133(B):88–92CrossRef
12.
go back to reference Ross OA, O’Neill C, Rea IM, Lynch T, Gosal D, Wallace A, Curran MD, Middleton D, Gibson JM (2004) Functional promoter region polymorphism of the proinflammatory chemokine IL-6 gene associates with Parkinson’s disease in the Irish. Hum Immunol 65:340–346CrossRefPubMed Ross OA, O’Neill C, Rea IM, Lynch T, Gosal D, Wallace A, Curran MD, Middleton D, Gibson JM (2004) Functional promoter region polymorphism of the proinflammatory chemokine IL-6 gene associates with Parkinson’s disease in the Irish. Hum Immunol 65:340–346CrossRefPubMed
13.
go back to reference Infante J, Garcia-Gorostiaga I, Sanchez-Juan P, Sánchez-Quintana C, Gurpegui JL, Rodríguez-Rodríguez E, Mateo I, Berciano J, Combarros O (2008) Inflammation-related genes and the risk of Parkinson’s disease: a multilocus approach. Eur J Neurol 15:431–433CrossRefPubMed Infante J, Garcia-Gorostiaga I, Sanchez-Juan P, Sánchez-Quintana C, Gurpegui JL, Rodríguez-Rodríguez E, Mateo I, Berciano J, Combarros O (2008) Inflammation-related genes and the risk of Parkinson’s disease: a multilocus approach. Eur J Neurol 15:431–433CrossRefPubMed
14.
go back to reference Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simón J, van der Brug M, López de Munain A, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D, Carrera IM, Pena AS, de Silva R, Lees A, Martí-Massó JF, Pérez-Tur J, Wood NW, Singleton AB (2004) Cloning of the gene containing mutations that causes PARK8-linked Parkinson’s disease. Neuron 44:595–600CrossRefPubMed Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simón J, van der Brug M, López de Munain A, Aparicio S, Gil AM, Khan N, Johnson J, Martinez JR, Nicholl D, Carrera IM, Pena AS, de Silva R, Lees A, Martí-Massó JF, Pérez-Tur J, Wood NW, Singleton AB (2004) Cloning of the gene containing mutations that causes PARK8-linked Parkinson’s disease. Neuron 44:595–600CrossRefPubMed
15.
go back to reference Haugarvoll K, Uitti RJ, Farrer MJ, Wszolek ZK (2006) LRRK2 gene and tremor dominant parkinsonism. Arch Neurol 63:1346–1347CrossRefPubMed Haugarvoll K, Uitti RJ, Farrer MJ, Wszolek ZK (2006) LRRK2 gene and tremor dominant parkinsonism. Arch Neurol 63:1346–1347CrossRefPubMed
16.
go back to reference Healy DG, Falchi M, O’Sullivan SS, Bonifati V, Durr A, Bressman S, Brice A, Aasly J, Zabetian CP, Goldwurm S, Ferreira JJ, Tolosa E, Kay DM, Klein C, Williams DR, Marras C, Lang AE, Wszolek ZK, Berciano J, Schapira AH, Lynch T, Bhatia KP, Gasser T, Lees AJ, Wood NW (2008) International LRRK2 consortium. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case–control study. Lancet Neurol 7:583–590CrossRefPubMedPubMedCentral Healy DG, Falchi M, O’Sullivan SS, Bonifati V, Durr A, Bressman S, Brice A, Aasly J, Zabetian CP, Goldwurm S, Ferreira JJ, Tolosa E, Kay DM, Klein C, Williams DR, Marras C, Lang AE, Wszolek ZK, Berciano J, Schapira AH, Lynch T, Bhatia KP, Gasser T, Lees AJ, Wood NW (2008) International LRRK2 consortium. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a case–control study. Lancet Neurol 7:583–590CrossRefPubMedPubMedCentral
17.
go back to reference Hashad DI, Abou–Zeid AA, Achmawy GA, Saad-Allah HM, Saad MA (2011) G20195 mutation of the leucine-rich repeat kinase 2 gene in a cohort of Egyptian patients with Parkinson’s disease. Genet Test Mol Biomark 15(12):861–866CrossRef Hashad DI, Abou–Zeid AA, Achmawy GA, Saad-Allah HM, Saad MA (2011) G20195 mutation of the leucine-rich repeat kinase 2 gene in a cohort of Egyptian patients with Parkinson’s disease. Genet Test Mol Biomark 15(12):861–866CrossRef
Metadata
Title
Interleukin-18 promoter polymorphisms and idiopathic Parkinson disease: an Egyptian study
Authors
Ebtesam Fahmy
Amany Rabah
Sahar Sharaf
Hanan Helmy
Ahmed Kamal
Publication date
01-06-2019
Publisher
Springer International Publishing
Published in
Acta Neurologica Belgica / Issue 2/2019
Print ISSN: 0300-9009
Electronic ISSN: 2240-2993
DOI
https://doi.org/10.1007/s13760-018-0927-7

Other articles of this Issue 2/2019

Acta Neurologica Belgica 2/2019 Go to the issue